InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,399.22
(
-0.51%
)
US TECH 100
18,362.00
(
-0.93%
)
Dow Jones
39,935.07
(
0.20%
)
Brent Oil
81.73
(
0.23%
)
Bitcoin
66,389.44
(
0.91%
)
Post# of 252682
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: exwannabe post# 87207

Wednesday, 12/09/2009 3:45:46 PM

Wednesday, December 09, 2009 3:45:46 PM

Post# of 252682
IMGN prior data

The comparison to a previous trial included both HER2+ and -, when looking at just HER2+ (which this trial was) the numbers were 32% in the previous trial.



That's not correct. Patients all had to be HER2+ to be on the trial. The ASCO 2009 data was in HER2+ patients. The ITT ORR for all patients was 25% and the DCR was 34.8%. ORR in Tykerb failures was 23.9% and the DCR was 35.8%.

Roach can't comment because the poster hasn't been presented and won't be until 12/12.

Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up